Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Pulmovant, Inc.

Clinical trials sponsored by Pulmovant, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New combo therapy for lung scarring and high blood pressure under study Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1 Completed 1

New inhaled drug aims to ease lung scarring and heart strain

Disease control Ongoing

This Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…

Phase 2 • Sponsor: Pulmovant, Inc. • Aim: Disease control

Last updated Sep 12, 2026 00:00 UTC